2019 LakePharma Symposium

LakePharma Symposium - 2019

LakePharma 2019 Symposium successfully covered topics in cell and gene therapies. The conference was well received by over 300 attendees and vendors. 


Thursday, October 10, 2019


South San Francisco Conference Center, 255 South Airport Boulevard, South San Francisco, CA 94080

Organizing Committee:

Hua Tu, Ph.D.                                  CEO, LakePharma, Inc.

Norman Garceau, Ph.D.                  VP, Technical Operations, LakePharma, Inc.

Brian Zabel, Ph.D.                           Senior Director, Discovery Immunology, LakePharma, Inc.




Alan Ashworth, Ph.D., FRS
President of Helen Diller Family Comprehensive Cancer Center at UCSF

Michael Boychyn, Ph.D.
Vice President of Process
Development at REGENXBIO Inc.

Dean Felsher, MD, Ph.D.
Director of Oncology Research, 
Director of Translational Research
and Applied Medicine at Stanford

Everett Meyer, MD, Ph.D.
Medical and Scientific Director,
Cellular Therapy Facility
at Stanford University

Madhusudan Peshwa, Ph.D.
Chief Technology Officer of Global Cell
Therapy at GE Healthcare

David Schaffer, Ph.D.
Director of the Berkeley
Stem Cell Center at UC Berkeley

Hua Tu, Ph.D.
President and CEO of LakePharma


       Pam Contag Ph.D.
          CEO, Bioeclipse


8:00 am -  5:30 pm, Thursday October 10, 2019      View full agenda here >>  |  Download PDF here >>



Directed Evolution of Novel Adeno-Associated Viral Vectors for Clinical Gene Therapy, David Schaffer, Ph.D., UC Berkeley


A Platform for Identifying Strategies for Reversing Cancer and Restoring the Immune Response, Dean Felsher, MD, Ph.D., Stanford University


Synthetic Lethal Approaches to Cancer Therapy, Alan Ashworth, Ph.D. FRS, UCSF


Clinical and Pre-Clinical Approaches Using T Regulatory Cells to Prevent or Treat Graft-versus-Host Disease, Everett Meyer, MD, Ph.D., Stanford University


The Combination of Immune Cells and Oncolytic Virus Creates A Unique Multi-Mechanistic Biotherapy for Treatment of Refractory Solid Tumors, Pam Contag, Ph.D., Bioeclipse


Comparison of Baculovirus (BV)-Sf9 and HEK293 Expression Systems for the Production of Adeno-Associated Virus (AAV) Vectors, Michael Boychyn, Ph.D., REGENXBIO


Industrializing the Manufacture of Cell and Gene Therapies, Madhusudan Peshwa, Ph.D., GE Healthcare


From CRO to CRDMO, LakePharma's Technology Development in Meeting Next-Generation Therapeutics Needs, Hua Tu, Ph.D., LakePharma



Parallel Lunch Workshops:

Alt-R CRISPR Genome Editing: Innovation Driving Solutions for HDR, Specificity, and Off-Target Analysis
Integrated DNA Technologies, Inc. | View Abstract


Integrated Workflow Solutions for Development of Cellular Therapies
Thermo Fisher Scientific | View Abstract


Expanding SPR Throughput Orders of Magnitude to Accelerate Therapeutic Antibody Discovery
Carterra | View Abstract


Panel Discussion on Cell Therapy GMP Manufacturing
LakePharma  | View Abstract


Please contact symposium@lakepharma.com for more information.

  • Sponsors: